Larry Edwards, La Jolla Pharmaceutical president and CEO
La Jolla exits to Innoviva in a deal that caps 33 years marked by misses in lupus, malaria and beta thalassemia
Thirty-three years after opening its doors and after many attempts at getting a lupus drug across the finish line, La Jolla Pharmaceutical is now wrapping …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
